Codexis (CDXS) | Financial Analysis & Statements
Codexis Inc. Micro-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
38.9M
Gross Profit
36.9M
94.75%
Operating Income
14.0M
35.89%
Net Income
9.6M
24.67%
EPS (Diluted)
$0.11
Balance Sheet Metrics
Total Assets
147.8M
Total Liabilities
97.3M
Shareholders Equity
50.5M
Debt to Equity
1.92
Cash Flow Metrics
Operating Cash Flow
17.4M
Free Cash Flow
19.6M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Codexis Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 70.4M | 59.3M | 70.1M | 138.6M | 104.8M |
| Cost of Goods Sold | 9.3M | 16.3M | 12.8M | 38.0M | 22.2M |
| Gross Profit | 61.0M | 43.1M | 57.3M | 100.6M | 82.5M |
| Gross Margin % | 86.7% | 72.6% | 81.7% | 72.6% | 78.8% |
| Operating Expenses | |||||
| Research & Development | 52.3M | 46.3M | 58.9M | 80.1M | 55.9M |
| Selling, General & Administrative | 47.1M | 55.1M | 53.2M | 52.2M | 49.3M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 99.4M | 101.4M | 112.1M | 132.3M | 105.2M |
| Operating Income | -38.3M | -58.4M | -54.8M | -31.7M | -22.7M |
| Operating Margin % | -54.5% | -98.3% | -78.1% | -22.9% | -21.7% |
| Non-Operating Items | |||||
| Interest Income | 2.6M | 3.7M | 4.2M | 1.4M | 459.0K |
| Interest Expense | 4.8M | - | - | - | - |
| Other Non-Operating Income | -3.4M | -10.6M | -25.5M | -3.0M | 1.1M |
| Pre-tax Income | -43.9M | -65.2M | -76.2M | -33.3M | -21.1M |
| Income Tax | 47.0K | 34.0K | 69.0K | 276.0K | 189.0K |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -44.0M | -65.3M | -76.2M | -33.6M | -21.3M |
| Net Margin % | -62.5% | -110.0% | -108.7% | -24.2% | -20.3% |
| Key Metrics | |||||
| EBITDA | -30.5M | -53.2M | -31.6M | -18.3M | -16.8M |
| EPS (Basic) | - | $-0.89 | $-1.12 | $-0.51 | $-0.33 |
| EPS (Diluted) | - | $-0.89 | $-1.12 | $-0.51 | $-0.33 |
| Basic Shares Outstanding | - | 73408000 | 68131000 | 65344000 | 64568000 |
| Diluted Shares Outstanding | - | 73408000 | 68131000 | 65344000 | 64568000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Codexis Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 50.8M | 19.3M | 65.1M | 114.0M | 116.8M |
| Short-term Investments | 27.4M | 54.2M | - | - | 0 |
| Accounts Receivable | 8.8M | 11.9M | 10.0M | 31.9M | 25.0M |
| Inventory | 1.8M | 1.8M | 2.7M | 2.0M | 1.2M |
| Other Current Assets | 5.6M | 4.1M | 5.2M | 5.5M | 5.7M |
| Total Current Assets | 96.8M | 98.8M | 93.5M | 162.9M | 161.9M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 69.4M | 64.6M | 50.4M | 78.9M | 77.2M |
| Goodwill | 4.9M | 4.9M | 4.9M | 6.5M | 6.5M |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 2.5M | 2.1M | 2.3M | 1.9M | 1.8M |
| Total Non-Current Assets | 51.0M | 50.2M | 43.1M | 87.5M | 84.5M |
| Total Assets | 147.8M | 149.0M | 136.6M | 250.4M | 246.4M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 1.6M | 2.8M | 5.9M | 3.2M | 3.0M |
| Short-term Debt | 2.9M | 2.8M | 3.8M | 5.4M | 4.1M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 25.3M | 23.6M | 35.8M | 49.1M | 33.4M |
| Non-Current Liabilities | |||||
| Long-term Debt | 70.3M | 57.1M | 12.2M | 38.3M | 43.6M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 1.3M | 1.3M | 1.2M | 1.4M | 1.3M |
| Total Non-Current Liabilities | 72.0M | 58.4M | 14.1M | 56.5M | 48.6M |
| Total Liabilities | 97.3M | 82.1M | 49.9M | 105.6M | 82.0M |
| Equity | |||||
| Common Stock | 9.0K | 8.0K | 7.0K | 6.0K | 6.0K |
| Retained Earnings | -606.8M | -562.8M | -497.5M | -421.3M | -387.7M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 50.5M | 66.9M | 86.6M | 144.8M | 164.4M |
| Key Metrics | |||||
| Total Debt | 73.2M | 59.9M | 16.0M | 43.6M | 47.7M |
| Working Capital | 71.5M | 75.1M | 57.6M | 113.8M | 128.5M |
Balance Sheet Composition
Codexis Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -44.0M | -65.3M | -76.2M | -33.6M | -21.3M |
| Depreciation & Amortization | 5.2M | 4.9M | 9.9M | 10.3M | 5.9M |
| Stock-Based Compensation | 9.6M | 13.1M | 10.0M | 14.5M | 11.6M |
| Working Capital Changes | 8.1M | -12.9M | -17.4M | 21.4M | -5.4M |
| Operating Cash Flow | -19.7M | -60.7M | -73.7M | 12.6M | -9.1M |
| Investing Activities | |||||
| Capital Expenditures | -4.5M | -4.2M | -3.7M | -8.3M | -13.8M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -57.2M | -90.2M | -1.2M | -5.3M | -7.6M |
| Investment Sales | 85.1M | 37.5M | - | - | 0 |
| Investing Cash Flow | 23.5M | -57.0M | -4.9M | -13.6M | -21.4M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 9.9M | 29.5M | - | - | - |
| Debt Repayment | - | - | - | 0 | 0 |
| Financing Cash Flow | 26.3M | 58.5M | 7.7M | -1.5M | -1.4M |
| Free Cash Flow | -23.8M | -53.7M | -57.1M | 3.0M | -28.1M |
| Net Change in Cash | 30.1M | -59.1M | -70.8M | -2.6M | -31.9M |
Cash Flow Trend
Codexis Key Financial Ratios
Valuation Ratios
Forward P/E
-11.45
Price to Book
4.52
Price to Sales
3.25
PEG Ratio
-11.45
Profitability Ratios
Profit Margin
-62.47%
Operating Margin
35.89%
Return on Equity
-74.88%
Return on Assets
-16.14%
Financial Health
Current Ratio
3.82
Debt to Equity
144.88
Beta
2.08
Per Share Data
EPS (TTM)
$-0.50
Book Value per Share
$0.56
Revenue per Share
$0.81
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| CDXS | 229.0M | - | 4.52 | -74.88% | -62.47% | 144.88 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Adagene | 243.8M | - | 4.95 | -34.39% | -229.56% | 12.07 |
| Orchestra BioMed | 242.9M | - | 4.48 | -109.41% | -157.40% | 25.17 |
| Third Harmonic Bio | 242.8M | 12.46 | 0.89 | -19.94% | 0.00% | 1.10 |
Financial data is updated regularly. All figures are in the company's reporting currency.






